195 related articles for article (PubMed ID: 25108195)
1. Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanism.
Chaudhri RA; Hadadi A; Lobachev KS; Schwartz Z; Boyan BD
Biochim Biophys Acta; 2014 Nov; 1843(11):2796-806. PubMed ID: 25108195
[TBL] [Abstract][Full Text] [Related]
2. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).
Chaudhri RA; Olivares-Navarrete R; Cuenca N; Hadadi A; Boyan BD; Schwartz Z
J Biol Chem; 2012 Mar; 287(10):7169-81. PubMed ID: 22247547
[TBL] [Abstract][Full Text] [Related]
3. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model.
Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z
Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279
[TBL] [Abstract][Full Text] [Related]
4. 17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen receptor-alpha 36.
Schwartz N; Chaudhri RA; Hadadi A; Schwartz Z; Boyan BD
Horm Cancer; 2014 Feb; 5(1):22-32. PubMed ID: 24081562
[TBL] [Abstract][Full Text] [Related]
5. Role of ERα36 in membrane-associated signaling by estrogen.
Chaudhri RA; Schwartz N; Elbaradie K; Schwartz Z; Boyan BD
Steroids; 2014 Mar; 81():74-80. PubMed ID: 24252378
[TBL] [Abstract][Full Text] [Related]
6. Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.
Cohen DJ; Dennis CD; Deng J; Boyan BD; Schwartz Z
JBMR Plus; 2024 May; 8(5):ziae041. PubMed ID: 38644978
[TBL] [Abstract][Full Text] [Related]
7. Estradiol receptor profile and estrogen responsiveness in laryngeal cancer and clinical outcomes.
Schwartz N; Verma A; Muktipaty C; Bivens C; Schwartz Z; Boyan BD
Steroids; 2019 Feb; 142():34-42. PubMed ID: 29274403
[TBL] [Abstract][Full Text] [Related]
8. Expression and localization of estrogen receptor in human breast cancer and its clinical significance.
Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L
Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640
[TBL] [Abstract][Full Text] [Related]
9. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.
Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224
[TBL] [Abstract][Full Text] [Related]
10. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.
Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H
BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
[TBL] [Abstract][Full Text] [Related]
12. ERα36--Another piece of the estrogen puzzle.
Sołtysik K; Czekaj P
Eur J Cell Biol; 2015 Dec; 94(12):611-25. PubMed ID: 26522827
[TBL] [Abstract][Full Text] [Related]
13. Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.
Zhang XT; Ding L; Kang LG; Wang ZY
Oncol Rep; 2012 Jun; 27(6):2057-65. PubMed ID: 22426783
[TBL] [Abstract][Full Text] [Related]
14. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer.
Panneerselvam M; Muthu K; Ramadas K
Mol Biosyst; 2015 Nov; 11(11):2998-3010. PubMed ID: 26299756
[TBL] [Abstract][Full Text] [Related]
15. ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines.
Pelekanou V; Notas G; Kampa M; Tsentelierou E; Radojicic J; Leclercq G; Castanas E; Stathopoulos EN
Steroids; 2012 Aug; 77(10):928-34. PubMed ID: 22198466
[TBL] [Abstract][Full Text] [Related]
16. Estrogen signaling and estrogen receptors as prognostic indicators in laryngeal cancer.
Verma A; Schwartz N; Cohen DJ; Boyan BD; Schwartz Z
Steroids; 2019 Dec; 152():108498. PubMed ID: 31539535
[TBL] [Abstract][Full Text] [Related]
17. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
18. The role of ERα36 in cell type-specific functions of estrogen and cancer development.
Mahboobifard F; Dargahi L; Jorjani M; Ramezani Tehrani F; Pourgholami MH
Pharmacol Res; 2021 Jan; 163():105307. PubMed ID: 33246174
[TBL] [Abstract][Full Text] [Related]
19. A Role for Estrogen Receptor alpha36 in Cancer Progression.
Pagano MT; Ortona E; Dupuis ML
Front Endocrinol (Lausanne); 2020; 11():506. PubMed ID: 32849292
[TBL] [Abstract][Full Text] [Related]
20. 17β-Estradiol inhibits testosterone-induced cell proliferation in HepG2 by modulating the relative ratios of 3 estrogen receptor isoforms to the androgen receptor.
Xu Z; Liu J; Jianxin C; Yongliang Z; Pan X
J Cell Biochem; 2018 Nov; 119(10):8659-8671. PubMed ID: 30058741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
